What is the global market size of Non-Small Cell Lung Cancer Market?

Global non-small cell lung cancer market was valued at USD11.43 billion in 2021, and it is predicted to reach USD12.2 billion by 2028. The market is expected to grow at a CAGR of 6.3 % during the forecast period (2022–2028). Read More

Who are the key vendors in the Global Non-Small Cell Lung Cancer Market?

Top Players in the Global Non-Small Cell Lung Cancer Market 'GlaxoSmithKline plc.(US)','F. Hoffmann-La Roche Ltd (Switzerland)','Novartis AG, (Switzerland)','Eli Lilly And Company.(US)','Astrazeneca, Pfizer Inc. (UK)','Takeda Pharmaceutical Company Limited.(Japan)','Ono Pharmaceutical Co., Ltd.(Japan)','Boehringer Ingelheim International Gmbh(Germany)','Merck & Co., Inc.(US)','Celgene Corporation, Amgen Inc.(California)','Sanofi (France)','Johnson & Johnson Services, Inc. (US)','Sun Pharmaceutical Industries Ltd.(Mumbai)','Dr. Reddy’s Laboratories Ltd. (Hyderabad)','Allergen (Ireland)','Teva Pharmaceutical Industries Ltd. (Israel)','Bristol-Myers Squibb Company(US)','Astellas Pharma Inc(Japan) ' Read More

Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy) - Industry Forecast 2024-2031

Report ID: SQMIG25K2005 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 36 | Figures: 74

Global Non-Small Cell Lung Cancer Market News

In May 2020, Pfizer Inc.'s LORVIQUA medication, which is indicated for adult patients with advanced non-small cell lung cancer who have tested positive for ALK and have previously received treatment with alectinib or ceritinib as the first anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy, received a favourable opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).

Global Non-Small Cell Lung Cancer Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Non-Small Cell Lung Cancer Market size was valued at USD 23.66 billion in 2019 and is poised to grow from USD 26.94 billion in 2023 to USD 76.33 billion by 2031, growing at a CAGR of 13.9% in the forecast period (2024-2031).

Top Players in the Global Non-Small Cell Lung Cancer Market 'Roche', 'AstraZeneca', 'Merck & Co.', 'Bristol-Myers Squibb', 'Pfizer Inc.', 'Novartis AG', 'Eli Lilly and Company', 'Celgene Corporation', 'Boehringer Ingelheim', 'AbbVie Inc.', 'Astellas Pharma Inc.', 'Takeda Pharmaceutical Company Limited', 'Sanofi S.A.', 'GlaxoSmithKline', 'Johnson & Johnson', 'Amgen Inc.', 'Ipsen S.A.', 'Eisai Co., Ltd.', 'Taiho Oncology, Inc.', 'Gilead Sciences, Inc.'

Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.